Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brivaracetam Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Epileptic Hippocampus in Alzheimer's Disease

NCT05899764
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Brivaracetam
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

NCT00368251
View directory record Official record
Conditions
Unverricht-Lundborg Disease
Interventions
Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

NCT01364597
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (BRV)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
28 Days to 17 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

NCT04379011
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Englewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT05109234
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 26 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

NCT01261325
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

NCT02088957
View directory record Official record
Conditions
Nonconvulsive Electrographic Seizures
Interventions
Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution, Phenytoin oral tablets
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Lexington, Kentucky • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

NCT00426673
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (ucb34714)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2008 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

NCT00761774
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
25
States / cities
Phoenix, Arizona • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00699283
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
43
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, levetiracetam, lorazepam, placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

NCT03405714
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
1 Month to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
The Bronx, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 4, 2026, 1:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

NCT00422422
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 16 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Gulf Breeze, Florida • Miami, Florida • Wellington, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

NCT00175916
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (ucb 34714)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
San Francisco, California • Gainesville, Florida • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT05639946
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
brivaracetam, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional

Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint

NCT03580707
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
BRV vs LEV in randomized double blinded, crossover fashion
Drug
Lead sponsor
Rosenfeld, William E., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

NCT01653262
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 1:48 PM EDT